

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab [Review of TA693] (ID4066)

Provisional Stakeholder List

| Consultees | Commentators (no right to submit or appeal) |
|---|---|
| <p><u>Company</u></p> <ul style="list-style-type: none"> • AstraZeneca (olaparib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency for Equality • Cancer 52 • Cancer Black Care • Cancer Equality • Eve Appeal • GO Girls • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Ovacome • Ovarian Cancer Action • The Robin Cancer Trust • South Asian Health Foundation • Specialised Healthcare Alliance • Target Ovarian Cancer • Tenovus Cancer Care • Wellbeing of Women • Women's Health Concern <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Geriatrics Society • British Gynaecological Cancer Society • British Psychosocial Oncology Society • British Society of Urogynaecology • Cancer Research UK • National Forum of Gynaecological | <p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Organon Pharma (bevacizumab) • Pfizer (bevacizumab) • Roche (bevacizumab) • Thornton & Ross (bevacizumab) • Zentiva (bevacizumab) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane UK • Cochrane Gynaecological Cancer Group • Genomics England |

Provisional stakeholder list for evaluation of olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab [Review of TA693] (ID4066)

Issue date: August 2022

| Consultees | Commentators (no right to submit or appeal) |
|---|--|
| <p>Oncology Nurses</p> <ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Obstetricians and Gynaecologists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • Welsh Government | <ul style="list-style-type: none"> • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency <p><u>Associated Guideline Group</u></p> <p>National Guideline Alliance (cancer, mental health, and women and children's health)</p> |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.